Advertisement
UK markets close in 1 hour 23 minutes
  • FTSE 100

    8,037.15
    +13.28 (+0.17%)
     
  • FTSE 250

    19,713.06
    +113.67 (+0.58%)
     
  • AIM

    753.80
    +4.62 (+0.62%)
     
  • GBP/EUR

    1.1626
    +0.0037 (+0.32%)
     
  • GBP/USD

    1.2433
    +0.0082 (+0.67%)
     
  • Bitcoin GBP

    53,663.81
    +439.16 (+0.83%)
     
  • CMC Crypto 200

    1,426.91
    +12.15 (+0.86%)
     
  • S&P 500

    5,049.50
    +38.90 (+0.78%)
     
  • DOW

    38,398.02
    +158.04 (+0.41%)
     
  • CRUDE OIL

    81.95
    +0.05 (+0.06%)
     
  • GOLD FUTURES

    2,343.70
    -2.70 (-0.12%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • DAX

    18,073.49
    +212.69 (+1.19%)
     
  • CAC 40

    8,083.15
    +42.79 (+0.53%)
     

How Amgen’s Prolia and Xgeva Performed in 3Q17

In 3Q17, Amgen’s (AMGN) Prolia generated revenues of around $464 million, which reflected ~22% growth on a year-over-year (or YoY) basis and an 8% decline on a quarter-over-quarter basis.